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Abstract 
Context.  In end-of-life care, delirium is often not recognized and poses unique 
management challenges, especially in the case of refractory delirium in the terminal phase. 
Objectives. To review:  delirium in the terminal phase context, specifically in relation to 
recognition issues; the decision-making processes and management strategies regarding its 
reversibility; the potential refractoriness of delirium to symptomatic treatment; and the role of 
sedation in refractory delirium. 
Methods. We combined multidisciplinary input from delirium researchers and 
knowledge users at an international delirium study planning meeting and relevant electronic 
database literature searches (Ovid Medline, Embase, PsycINFO and CINAHL) to inform this 
narrative review. 
Results. The overall management strategy for delirium at the end of life is directed by the 
patient’s prognosis in association with the patient’s goals of care. As symptoms of delirium are 
often refractory in the terminal phase, especially in the case of agitated delirium, the judicious 
use of palliative sedation is frequently required. However, there remains a lack of high level 
evidence for the management of delirium in the terminal phase, including the role of 
antipsychotics and optimal sedation strategies. For the family and health care staff, clear 
communication, education and emotional support are vital components to assist with decision 
making and direct the treatment care plan. 
Conclusion. Further research on the effectiveness of delirium management strategies in 
the terminal phase for patients and their families is required. Further validation of assessment  
tools for diagnostic screening and severity measurement are needed in this patient population. 
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Introduction 
Delirium is a distressing and complex neurocognitive syndrome that is recognized as an 
index of serious illness.  This is particularly evident in relation to its occurrence in palliative care 
settings, wherein patients by definition are faced with life-threatening illnesses, most commonly 
cancer (1). Given the projected population demographic changes, with a substantive proportional 
increase in the elderly (2,3), and an associated increase in cancer-related deaths (4), delirium is 
becoming an increasingly important issue in health care. Studies to date would suggest that many 
patients in palliative care settings experience some degree of delirium in the dying phase (5).  
Although delirium prevalence rates of 88% have been reported in the hours and days before 
death (6), the use of such loosely defined terms as terminal anguish or terminal restlessness 
suggests that in clinical practice delirium may not always be recognized as such in both end-of-
life care and in the more immediate terminal phase (7-9). 
Given the frequent and perceived natural accompaniment of delirium with the dying 
phase, this “terminal delirium” paradigm may become a self-fulfilling prophecy, insofar as it 
may foster an unduly fatalistic approach that overshadows the lesser appreciated potential for 
reversal, and thus the delirium episode and terminal phase association becomes a fait accompli. 
Reversibility depends on the etiologic factors and the stage of disease in conjunction with the 
goals of care (6,10).  
The association of delirium with the terminal phase may be strengthened further when a 
deep level of sedation, in the form of palliative sedation, is used to provide symptomatic 
treatment for delirium-related distress that is refractory to current clinical interventions. In 
addition to patient distress, the unresolved symptoms of a refractory agitated delirium can be 
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very distressing to families and challenging for the health care team, and further compounded at 
the end of life by impeded communication as a result of the delirium (11,12). A recent systematic 
review of palliative sedation suggests that delirium is one of the most common indications for 
palliative sedation (13). Although palliative sedation (sedation in the terminal phase) has been 
the subject of controversy (14), especially when the indications are not clearly defined, it is a 
necessary and ethically acceptable intervention (15,16). Thus the management of delirium in 
palliative care settings is perhaps not surprisingly associated with some clinically challenging 
dilemmas and potential controversy (17).  
Although this review is focused on delirium in the context of the dying phase, it will 
address issues of clinical relevance, particularly regarding the management approach in the 
broader end-of-life context.  More specifically, this review aims to 1) address issues regarding 
recognition and terminology; 2) outline the decision-making processes as part of optimal 
management prior to designating an episode of delirium as refractory; and 3) describe the role of 
palliative sedation in refractory delirium occurring in the dying phase. 
Methods 
Data Synthesis 
We combined multidisciplinary input from delirium researchers and knowledge users at 
an international delirium study planning meeting and relevant literature searches as our 
knowledge synthesis strategy in this review. The literature search to inform this narrative review 
was conducted in four electronic databases (Ovid Medline, Embase, PsycINFO and CINAHL) 
for publications between 1990 and December 18, 2013 to identify papers on the management of 
delirium at the end of life, including sedation. The search terms included “palliative care,” 
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“terminal care,” “hospice care,” “end of life,” “delirium,” “terminal restlessness” and “sedation” 
and results were limited to the English language and adults.  
Working Definitions  
Much of the terminology surrounding end-of-life care is ambiguous.  Consequently, for 
purposes of clarity and consistency, we chose to use a set of brief definitions or descriptions 
specifically for this review (Table 1). We sought to use previously published definitions where 
possible. Palliative sedation is described in full in the designated part of the following section. 
Results and Discussion 
Our literature search yielded a total of 6961 citations from Ovid Medline (52), Embase 
(45), PsycINFO (20) and CINAHL (6844). The first 300 abstracts in CINAHL (ordered 
according to relevance as determined by the CINAHL database), and the 117 abstracts from the 
other three databases were reviewed (S.B.). Full articles meeting our search criteria were 
retrieved and the content used to inform this narrative review. 
Exploring the “Terminal Delirium” Paradigm: Recognition Issues and Terminology  
In patients with advanced disease, delirium has been described as the “harbinger of 
death” (25). An agitated delirium frequently occurs in the last week of life (26). In the last hours 
and days of life, delirium is often a visible manifestation of a culmination of significant multi-
organ failure compounded by other irreversible factors. Poor prognostic factors include delirium 
severity; irreversible precipitating factors; a greater degree of cognitive impairment; the 
hypoactive subtype; and history of a previous episode of delirium. (6,25,27-29) With the 
presence of these factors, the health care team will often initiate conversations with families 
about a delirium episode being a poor prognostic sign (25).   
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In the terminal phase of illness, it can be challenging to use the currently available 
validated delirium screening and diagnostic tools, especially for hypoactive delirium and for 
patients with a reduced level of consciousness and communication because of natural disease 
progression (30-33). The final item on the observational Nursing Delirium Screening Scale (Nu-
DESC) (34) on psychomotor retardation was designed to detect hypoactive delirium, but may be 
rated by nurses observing increasing fatigue and patients spending more time in bed as part of 
the terminal phase. The Memorial Delirium Assessment Scale (MDAS), developed to rate 
delirium severity, can be prorated if patients are unable to participate in the assessment (35,36). 
The diagnosis of delirium in the terminal phase is often made following a global clinical 
assessment by an experienced practitioner using pattern recognition (37,38).  
  Historically, the term “terminal restlessness” has been used to describe features consistent 
with an agitated delirium in patients who were in the dying phase (39). The term encompassed a 
cluster of symptoms (with a variety of different descriptions) including: frequent non-purposeful 
motor activity, multifocal myoclonus, fluctuating levels of consciousness, cognitive failure, 
anxiety, sleep-wake cycle disturbance, and agitation (40,41). The word “restless” is not clinically 
specific, and can mean either physical (“unable to keep still”), or psychic (“worried, uneasy or 
anxious”) distress (42). Plucking at bed sheets and pulling off clothes are examples of the 
purposeless repetitive movements that are often seen. Moaning, groaning and facial grimacing 
often occur, which may be particularly distressing for family members who interpret their loved 
one to suddenly be in severe physical pain although they previously either had well-controlled 
pain or no pain. Therefore, families need support and explanatory education (43,44) to avoid 
misinterpretation of a delirious patient’s disinhibition and apparent increase in expression of 
pain. For example, in this context, a patient’s agitation is commonly exacerbated by bladder 
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distention secondary to urinary retention. Other factors causing agitation include fecal impaction, 
medication-induced akathisia and uncontrolled pain. Patients should be assessed for all these 
contributory factors and managed accordingly. As delirium challenges the assessment of physical 
and psychological symptoms, it may be appropriate to trial a single “rescue” dose of an opioid in 
addition to administration of an antipsychotic if uncontrolled pain cannot be excluded during a 
period of severe agitation. 
In addition to terminal restlessness, a variety of other terms that refer to similar clusters 
of symptoms also have been used in the literature, both interchangeably and as separate entities. 
These include “terminal agitation,” “terminal delirium,” and “terminal anguish” (40).  The term 
terminal anguish seemed to suggest an underlying and perhaps causal state of psychospiritual 
distress. Indeed, surveyed hospice professionals considered spiritual and psychosocial causes as 
frequently as physical causes for terminal restlessness (45).  As a result of this, preventive 
measures have been recommended for this state: meeting the spiritual and existential needs of the 
patient, providing an opportunity to resolve conflicts, and completing death preparation work 
(40,46).  Use of the label “terminal” in all the various terms implies a causal relationship 
between the terminal phase of illness, usually the 48–72 hours before death, and the symptoms of 
restlessness (42).  In turn, this can sometimes lead to a nihilistic approach to management, 
whereby a potentially reversible cause of delirium may be missed. Similar concerns relate to the 
associated state called “terminal cognitive failure,” where the cognitive impairments are 
emphasized more than motor activity changes, but with similar inherent presumptions as to cause 
and a likely association with delirium.  The use of nonspecific terminology and interchangeable 
clusters of symptoms confuses the important diagnostic challenge of determining whether the 
clinical presentation is the result of pain or discomfort, delirium, psychological distress, seizures, 
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or metabolic causes of myoclonus, all of which have different approaches to management. The 
role of neuroexcitatory opioid metabolites was historically suspected as contributing to the 
development of myoclonus (41,42).  In the past, benzodiazepines alone were used to provide 
symptomatic relief for agitation in this context (47), whereas adopting the practice of opioid 
switching as a therapeutic strategy occurred more recently.  
The use of parenteral (subcutaneous or intravenous) hydration to reverse the delirium 
associated with opioid toxicity is well established in palliative care practice but in the context of 
the patient who is actively dying, the use of parenteral hydration is a hugely contentious and 
emotive issue.  A recent review suggested that reversal of delirium was the only aspect of 
terminal symptom control and comfort care where the actively dying patient might derive benefit 
from parenteral hydration (48). There is an urgent need for more research to clarify the potential 
benefits and harms of parenteral hydration at the end of life (49). Meanwhile, the use of 
parenteral fluid as a delirium symptom control measure for a patient clearly in the final days of 
life must be accompanied by very clear and sensitive explanation of its role at the end of life; 
support for families and carers; and consensus that parenteral fluids will be frequently reviewed, 
and discontinued if side effects such as worsening respiratory secretions or edema outweigh the 
symptomatic benefit for the patient.  
Delirium Reversibility in End-of-Life Care 
At the end of life, the patient’s goals of care should be confirmed or established in the 
first instance. In practice, this is often clarified with the substitute decision maker (SDM), as the 
patient may not be able to participate in decision making. Some patients’ and families’ wishes 
delineate a clear focus solely on patient comfort, so that only delirium symptoms will be 
managed (with no attempts at reversal) in keeping with patient and family values. However, 
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efforts focused on comfort and delirium reversal need not be mutually exclusive. Underlying 
causes for the delirium episode should be sought if consistent with the patient’s goals of care, 
especially if the delirium precipitants can be easily identified. Furthermore effective treatments 
should be accessible and amenable to administration with minimal burden, thus ensuring no 
increased distress to the patient. A medication profile review and an increase in the 
Anticholinergic Risk Scale will assist in identifying potential deliriogenic medications that can 
be dose-reduced or discontinued (50,51). Apart from the imminently dying context (last hours of 
life), an opioid switch (with a reduction in opioid equianalgesic dose by 30-50%) also may be 
appropriate if signs of opioid-induced neurotoxicity are present, although there remains a lack of 
high level evidence for this strategy in delirious patients (52,53).  Although complete or partial 
reversal of the delirium may be possible, approximately 50% of delirium episodes in palliative 
care patients cannot be reversed, based on a study conducted in a tertiary palliative care unit in 
an acute care hospital (6). An episode of delirium is more likely to be irreversible if patients have 
experienced previous episodes of delirium or if the delirium is a result of a hypoxic or metabolic 
encephalopathy (6,28).  
By its inherent nature, delirium may be manifested by fluctuating symptoms, which may 
challenge the clinician’s estimation of prognosis. The patient’s estimated prognosis may 
influence the intensity of investigations and corrective interventions as recommended by the 
health care team in accordance with the agreed goals of care. As a health care professional, a 
significant challenge may be ascertaining that the terminal stage in the patient’s illness has 
indeed been reached. There will often be other accompanying clinical features to indicate that the 
patient’s prognosis is rapidly shortening, such as reduced performance status, anorexia, reduced 
oral intake, a reduced ability to swallow, weight loss (especially in the temples) as well as a rapid 
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trajectory of decline and other features of imminent death (such as changes in respiratory pattern, 
temperature and skin mottling) (54,55). If a patient’s prognosis is not clear and such treatment is 
consistent with their wishes, a time-limited trial of treatment of potential delirium precipitants 
may be appropriate, such as a trial of antibiotics for suspected infection. An optimal approach to 
delirium management with the aim of controlling distressing delirium symptoms in the terminal 
phase is summarized in a stepwise manner in Fig. 1.  
Symptomatic Treatment of Delirium in the Terminal Phase 
Patients who have recovered from an episode of delirium report significant distress, for 
both hyperactive and hypoactive clinical subtypes (11,12).  In contrast to aged care and intensive 
care populations, there is currently insufficient evidence to support non-pharmacological 
approaches in the management of delirium at the end of life (32,56). Potential contributors to 
agitation in the dying patient, such as pain, urinary retention, and fecal impaction, also should be 
assessed and managed accordingly. Distressing delirium symptoms such as hallucinations or 
delusions as well as patient safety concerns may require pharmacological management, 
regardless of whether the underlying causes are being pursued or not.  
Currently there is limited research evidence, with no placebo controlled trial to support 
the use of antipsychotics in palliative care patients with delirium (57-60).  Published in 1996, a 
randomized double-blind trial in 30 terminally ill AIDS patients compared haloperidol, 
chlorpromazine and lorazepam (61). Low-dose haloperidol and chlorpromazine were found to be 
clinically effective, but lorazepam used as a single agent worsened symptoms of delirium. The 
results of a phase III study in palliative care patients, comparing orally administered haloperidol, 
risperidone and placebo, are awaited (62).   
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
13
Delirium clinical practice guidelines (CPGs) encompassing the dying patient also are 
limited (63), with the National Institute for Health and Clinical Excellence (NICE) guidelines 
specifically excluding “people receiving end-of-life care” (defined by NICE as the “last few days 
of life”) (64).  It should be noted that clinicians in other specialties, such as geriatrics, internal 
medicine and oncology, vary in their management of delirium, including in patients in the 
terminal phase (65,66).  We have arbitrarily designated three different approaches to 
symptomatic treatment, based mainly on the goals of care and increasing levels of sedation. We 
acknowledge that these approaches are based on current palliative care clinical opinion, as there 
is a lack of high level evidence at this time (Fig. 1).  
Pharmacological Intervention With Minimal Sedation Approach. A minimal sedation 
approach to management consists of administering appropriately titrated doses of a non-sedating 
typical (e.g., haloperidol) or atypical antipsychotic (59). Although the aim is not primarily to 
sedate the patient, it must be acknowledged that some of the newer or atypical antipsychotics 
such as olanzapine or risperidone are more likely (in a dose-dependent manner) to cause sedation 
than haloperidol. Patients with hypoactive delirium have been shown to have a poorer response 
to olanzapine (67).  Patients with hypoactive delirium are often lethargic and somnolent and thus 
may require non-sedating antipsychotics for distressing symptoms, but not necessarily sedating 
medications.   Further research is needed to determine the optimal management of refractory 
hypoactive delirium, and indeed of all motoric subtypes, at the end of life. 
Pharmacological Intervention With a More Sedating Approach or Intermittent Sedation. 
This approach involves changing from a non-sedating to a more sedating antipsychotic (e.g., 
methotrimeprazine [levomepromazine] or chlorpromazine), and is indicated if the patient 
remains agitated despite appropriate doses of minimally sedating antipsychotics. The more 
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sedating approach also may include intermittent sedation for agitated delirium. This specific 
practice may involve the addition of low “rescue” doses of a short-acting benzodiazepine (e.g., 
midazolam or lorazepam) to the treatment regimen. Anecdotally, the strategy of combining a 
short-acting benzodiazepine with an antipsychotic is frequently used in the acute management of 
severe agitation in a delirious patient (68-70), as use of a benzodiazepine alone may worsen 
delirium (61).  Short-term sedation with a benzodiazepine also may be warranted in patients who 
are exhausted because of a lack of sleep. Sleep deprivation is well-documented as a precipitating 
factor for delirium (3).  If there is uncertainty regarding a patient’s condition and the 
determination of delirium irreversibility, a trial of “respite” sedation for a short predetermined 
time period may be warranted. This may successfully control the patient’s symptoms, allow an 
opportunity for reassessment and eliminate the need for pursuing continuous palliative sedation 
in this instance (71).  
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Designation of Refractory Delirium at the End of Life. If a dying patient has a non-
reversib-le delirium with persistent and distressing agitated symptoms, then palliative sedation 
should be considered. An outline of the process in determining the potential need for palliative 
sedation is shown in Fig. 1. There is an imperative need to control ongoing symptoms of an 
irreversible agitated delirium for patient comfort, to reduce the level of distress for both the 
patient and their family, and consequently facilitate a more “peaceful” death (72). 
Communication among the interprofessional health care team members and with the patient and 
family, or other SDM, to discuss the role of sedation in an individual patient’s treatment plan is 
essential. Sedation may be intermittent or continuous, as in continuous palliative sedation. 
Families may have ambivalent feelings towards the use of sedating medications and reducing the 
capacity for communication with their loved one (73,74). Conflict may be reduced by positive 
communication between the family and the health care team, recognizing that family members 
may have different individual concerns that need to be addressed (75). Information should be 
provided according to the specific elicited needs of family members. This communication and 
information-giving can be facilitated by a scheduled meeting involving the interprofessional 
team (with as many different disciplines in attendance as resources and time permit) and the 
SDM and core family members. Regular follow-up involving less formal “check in” meetings 
with family members provides an opportunity to further meet their informational and emotional 
needs and actively provide ongoing education and support (Fig. 1). Further studies exploring the 
effectiveness and optimal delivery of these strategies are required (44,76).  
The presence of delirium itself has been identified as a factor causing increased difficulty 
in the decision-making process for family members (77).  Delirium increases distress for family 
members (11,12), especially at the end of life where communication is impaired (73,74,78). In 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
16
addition to agitated delirium, family member distress is increased by the presence of cognitive 
impairment in the patient (79).  Families vary in their comfort level of witnessing delirious 
behavior and express both positive and negative emotions (78). Some families may prefer the 
patient to be minimally sedated although remaining confused and intermittently agitated, 
whereas other families may be much more at ease if the patient is more deeply sedated, sleeping 
peacefully and felt not to be aware of distress. Family members also may feel burdened in 
making proxy decisions at this time (74).  Ideally, a patient will have had an opportunity to 
clarify his or her values for end-of-life care to their family or SDM as well as the care team 
before communication becomes impaired, although clearly this is not always the case. The need 
for emotional support should be assessed in all family members and provided as necessary. 
Palliative Sedation: Deep and Continuous Sedation for Relief of Refractory Symptoms in 
Dying Patients 
Table 1 includes a working definition of palliative sedation, and Table 2 provides 
examples of other published definitions of palliative sedation from CPGs, frameworks and 
position statements. The degree of reduction in the patient’s level of consciousness should be 
proportionate to the magnitude of the refractory symptom/s in order to relieve the patient’s 
suffering. When applied appropriately, continuous palliative sedation is an ethically justified 
therapeutic option at the end of life (i.e., last hours, days or one to two weeks of life) when all 
other available options are exhausted and “when there is a lack of other methods for palliation 
within an acceptable time frame and without unacceptable adverse effects (refractoriness)” 
(15,86). The use of proportionate sedation is not associated with hastening death (13).  
The term “palliative sedation” started to appear in the literature in 2000 (87,88). Over the 
years, many other terms have been used to describe sedation for symptomatic relief at the end of 
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life, including “terminal sedation,” “continuous deep sedation,” and “palliative sedation 
therapy.” The evolution of the terminology for this type of sedation has been clearly outlined in a 
recent review paper by Papavasiliou et al. (89). However, this whole issue requires further 
discussion and consensus. Lack of a clear consensus definition may lead to an underestimation of 
the frequency of use of palliative sedation in clinical practice. In addition, a standardized 
worldwide definition is required in order to better compare practices and research internationally.  
Indications. Palliative sedation is used in the management of multiple refractory 
symptoms at the end of life, and delirium is the most common indication (13,24,90,91). Other 
indications include symptom distress in association with refractory dyspnea, intractable seizures, 
terminal hemorrhage and uncontrolled pain. 
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  Initiating Continuous Palliative Sedation.  The process culminating in the decision to 
initiate continuous palliative sedation involves the patient, whenever possible, their family and 
the interprofessional health care team. In the absence of family, a designated SDM or legally 
appointed power of attorney (POA) should be included in the discussion. The use of a criteria 
checklist is proposed as a prerequisite to ensure the appropriateness of palliative sedation (92). 
These criteria include the presence of a progressive, incurable illness with a limited life 
expectancy, and the informed consent of the patient or SDM. Consultation with a specialist 
palliative care team is recommended to ensure that the symptom/s are refractory to all treatments 
and interventions. Family members may need confirmation regarding the refractoriness of the 
symptom/s and that no other options remain to manage these intractable symptoms and patient 
distress (93).  The anticipated impact of sedation on communication with the patient also should 
be discussed. Throughout this process, clear documentation is essential. 
In addition to published frameworks and position statements (Table 2), a few CPGs on 
palliative sedation have been developed (21,80,94).  Guidelines should specify the nursing 
responsibilities according to their various roles (e.g., specialist palliative care nurse versus 
generalist) (95). Further research evaluating the effectiveness and adherence to CPGs is required 
(96,97).  
Medications Used for Palliative Sedation.   The level of evidence for the efficacy of 
medications used for sedation is low and prospective comparative studies are needed to 
determine the most effective and safest methods (98,99).  The choice of medication will vary 
depending on the indication/s for palliative sedation and also on the care setting (e.g., inpatient 
versus community) and drug availability. It is paramount that the medication provides 
proportional sedation; thus the aim is to use the lowest possible dose of medication to achieve 
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the lightest level of sedation that provides symptom relief and comfort. In order to control 
symptoms of an agitated delirium and relieve suffering in the terminal phase, continuous 
sedation will often need to be titrated to a level that reduces a patient’s level of consciousness, 
thereby also reducing their capacity for communication. 
Midazolam, with a rapid onset of action, is the most commonly used medication for 
palliative sedation (13).  Although it is easy to titrate the dose up or down fairly rapidly, it needs 
to be administered as a constant infusion to achieve continuous sedation because of its short half-
life. Midazolam is occasionally ineffective or can, as with other benzodiazepines, cause a 
paradoxical increase in agitation (100,101). Other medications reportedly have been used for 
sedation depending on location of care and drug availability. These include lorazepam, 
chlorpromazine, levomepromazine (methotrimeprazine) (not available in the U.S.), phenobarbital 
(phenobarbitone) and propofol (13,83,102,103).  Medications for symptom relief, e.g., 
antipsychotics for delirium, opioids for pain and/or dyspnea, should also be continued. 
Monitoring Palliative Sedation.  The use of standardized instruments is a critical 
component of management to ensure best practice in the monitoring of the level of sedation and 
efficacy of medications, as well as enhancing documentation and ensuring patient safety 
(15,83,85,104).  These tools should assess sedation levels as well as levels of distress in dying 
patients receiving palliative sedation.  
Over the years, several instruments have been developed to monitor sedation and/or 
agitation levels, mostly in intensive care settings. These include the Ramsey Scale (105), the 
Rudkin Scale (106), the Riker Sedation-Agitation Scale (SAS) (107), and the Richmond 
Agitation-Sedation Scale (RASS) (108).  The Consciousness Level Scale was specifically 
developed and validated in the palliative care setting (109).  It assesses the level of consciousness 
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only, and not agitation. Similarly, the modified Rudkin scale, also validated in the palliative care 
setting, assesses consciousness alone (110).  The Communication Capacity Scale has a single 
item on conscious level, with three other items related to patient communication and one on 
voluntary movement, whereas the complementary Agitation Distress Scale rates agitation 
distress (111).  These scales were initially studied in terminally ill cancer patients with delirium 
and later used in palliative care inpatients receiving palliative sedation (98).  In 2009, the 
European Association for Palliative Care’s Expert Working Group on Palliative Sedation 
recommended the use of the RASS or similar instrument in the monitoring of palliative sedation 
(15).  The RASS was originally developed and validated in adult patients in the intensive care 
setting (108,112).  This simple instrument requires brief health care professional observation of 
the patient in order to provide a quantitative score (range +4 to -5) on the patient’s level of 
agitation or sedation at the time of assessment. It should be noted that the original RASS 
instrument provides a snapshot measure of “agitation,” as opposed to being a formal screening 
assessment for “agitated delirium.” Although the RASS is currently used in many palliative care 
settings (90,96,113,114), there are few reports examining the reliability of modified versions in 
patients with advanced cancer (115).  A version of the RASS modified for palliative care 
inpatients, the RASS-PAL, demonstrated high inter-rater reliability in a recent pilot study (116).  
Further research is needed on the development and validation of sedation and agitation 
monitoring instruments specific to palliative care populations. 
Addressing Ongoing Communication and Other Concerns During Palliative Sedation.  
Family members may experience significant distress when their relative is receiving continuous 
palliative sedation (117).  They may need reassurance that the sedated patient is no longer 
distressed (93). Occasionally, families request sedation to be reduced or discontinued once the 
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patient appears calm, in the hope of resuming meaningful communication (75).  Throughout the 
process of palliative sedation, ongoing emotional support and frequent information should be 
provided to both the family and the health care team (118-121).  
Conclusion 
Uniform terminology is required for delirium in the terminal phase. With the challenges 
of recognizing delirium in dying patients, further research is needed on validated diagnostic tools 
that can be reliably used in this patient population. Potentially pivotal decision-making 
challenges arise at various points in end-of-life delirium management, especially in the terminal 
phase.  The overall management strategy is directed by the patient’s prognosis in association 
with the patient’s goals of care, as influenced by patient and family values. As symptoms of 
agitated delirium are often refractory at this time, the judicious use of palliative sedation is 
frequently required. For the family and health care staff, clear communication, education and 
emotional support are vital components to assist with decision making and direct the treatment 
care plan. The current evidence base to inform practice is lacking and further research (Table 3) 
on the effectiveness of such management strategies for dying patients with delirium and their 
families is urgently required.  
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Table 1. Working Definitions of Terms Used in This Paper 
End of life: the presence of progressive life-limiting disease in a patient with a prognosis of months or 
less. This definition is based on a systematic review of prognostic terminology in palliative care by Hui et 
al.18  
Actively dying (viewed as synonymous with the dying or terminal phase): “the hours or days preceding 
imminent death during which time the patient’s physiologic functions wane”.19 Eagar et al. provided 
common clinical descriptors of a “terminal care phase” in their definitions of palliative care phases for a 
case-mix classification.
20 
We have opted to use the term dying phase in our review and view it as being 
synonymous with ‘actively dying’. 
Refractory symptom or refractory delirium: a symptom is defined as refractory if it continues to cause 
distress despite the use all other possible and tolerable symptomatic treatments that do not 
compromise consciousness. Furthermore, following careful assessment and communication, there is 
consensus among patient or substitute decision maker, family members, attending physician, and 
interprofessional care providers that no other treatments are tolerably acceptable or likely to provide 
adequate relief within an acceptable time frame.
21
 We use the term refractory delirium or distress 
related to refractory delirium in the same context as this description of refractory symptom. 
Goals of care: are the intended purposes of health care interventions and support as recognized by both 
a Patient or Substitute Decision Maker and the Health Care Team.
22
  
Agitated delirium: based on psychomotor classification of delirium, this refers to a hyperalert episode of 
delirium in which features of hyperactivity (motor restlessness) are evident.
23 
 
Terminal delirium: this refers to an episode of delirium that occurs in the dying phase and thus implies 
that reversal will not be pursued.  
Palliative sedation or sedation in the terminal phase: this has been defined as “the intentional 
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administration of sedative drugs in dosages and combinations required to reduce the consciousness of a 
terminal patient as much as necessary to adequately relieve one or more refractory symptoms”.
24
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Table 2. Examples of Definitions of “Palliative Sedation” from Clinical Practice Guidelines, Frameworks 
and Position Statements 
Origin/ Year  Reference  
Sedation Guideline 
Task Force in Japan:  
Clinical guideline 
2005 
“Palliative sedation therapy is defined as (1) the 
use of sedative medications to relieve suffering by 
the reduction in patient consciousness level or (2) 
intentional maintenance of reduction in patient 
consciousness level resulting from symptomatic 
treatments.” 
 
“Palliative sedation therapy is classified according 
to duration and degree of sedation, and is 
described as (sic: a) combinations of these 
classifications (e.g., continuous-deep sedation, 
intermittent-mild sedation).” 
Morita et al.80, p. 717 
 
American Academy 
of Hospice and 
Palliative Medicine 
(AAHPM): Position 
statement 
2006 
“Palliative sedation (PS): The use of sedative 
medicine at least in part to reduce patient 
awareness of distressing symptoms that are 
insufficiently controlled by symptom-specific 
therapies. The level of sedation is proportionate 
to the patient’s level of distress, and alertness is 
preserved as much as possible.” 
 
http://www.aahpm.org/posi
tions/default/sedation.html 
September 15, 2006
81
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“Palliative sedation (PS) to unconsciousness: The 
administration of sedatives to the point of 
unconsciousness, when less extreme sedation has 
not achieved sufficient relief of distressing 
symptoms. This practice is used only for the most 
severe, intractable suffering at the very end of 
life.” 
Committee on 
National Guideline 
for Palliative 
Sedation, Royal 
Dutch Medical 
Association: 
Guideline for 
palliative sedation 
2005 
“Palliative sedation is ‘the intentional lowering of 
consciousness of a patient in the last phase of his 
or her life’.” 
“The objective of palliative sedation is to relieve 
suffering.” 
“It is very important that palliative sedation is 
given for the right indication, proportionally and 
adequately.” 
Verkerk et al. 
82, p. 667
 
 
Expert panel 
(international group 
of palliative care 
clinicians): 
Recommendations 
for standards 
2007 
“Palliative sedation therapy (PST) is the use of 
specific sedative medications to relieve intolerable 
suffering from refractory symptoms by a 
reduction in patient consciousness.” 
 
“Refractory symptoms are symptoms for which all 
possible treatment has failed, or it is estimated 
that no methods are available for palliation within 
De Graeff and Dean
83, p. 68
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the time frame and the risk-benefit ratio that the 
patient can tolerate.” 
 
European 
Association for 
Palliative Care 
(EAPC):  
Framework 
2009 
“Therapeutic (or palliative) sedation in the context 
of palliative medicine is the monitored use of 
medications intended to induce a state of 
decreased or absent awareness (unconsciousness) 
in order to relieve the burden of otherwise 
intractable suffering in a manner that is ethically 
acceptable to the patient, family and health-care 
providers.”  
Cherny 2009
15
 
(Page 581) 
 
Palliative Sedation 
Task Force of the 
National Hospice 
and Palliative Care 
Organization 
(NHPCO) Ethics 
Committee:  
Position statement 
2010 
“Palliative sedation is the lowering of patient 
consciousness using medications for the express 
purpose of limiting patient awareness of suffering 
that is intractable and intolerable.” 
 
“This statement addresses the use of palliative 
sedation only for patients who are terminally ill 
and whose death is imminent.”  
Kirk and Mahon
84, pp. 914, 915
 
 
Canadian Society of 
Palliative Care 
Physicians 
Taskforce: 
“Continuous palliative sedation therapy (CPST) is 
the use of ongoing sedation continued until the 
patient’s death.” 
“CPST is indicated only for refractory and 
Dean et al. 
85, pp. 870, 871
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Framework 
2012 
intolerable suffering, usually in the last 2 weeks of 
life.” 
“Sedation should be carefully titrated to 
adequately relieve suffering.” 
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Table 3. Questions for the Future Research Agenda in the Management of Delirium in Dying Patients 
a
 
Assessment: 
• What are the most appropriate tools for the diagnosis of delirium, including hypoactive subtype, 
in the dying phase?  
• What are the most reliable validated tools to monitor treatment efficacy in this population? 
• What is the reliability of instruments specifically developed for the monitoring of sedation and 
agitation during palliative sedation? 
Management of delirium: 
• What are the efficacy and harms of non-pharmacological interventions in the dying phase? 
• What are the comparative efficacies and harms of pharmacological interventions in the dying 
phase? 
o What is the role for antipsychotics and rescue low dose short-acting benzodiazepine? 
o What are appropriate dosing and titration strategies for non-sedating and sedating 
antipsychotics? 
• What is the efficacy of multicomponent interventions for management of delirium symptoms? 
o Are different interventions required for different delirium subtype, i.e. hyperactive vs. 
hypoactive? 
Management of refractory delirium at the end of life: 
• What is the optimal management of refractory delirium with an agitated component? 
• What is the optimal management of refractory delirium that is predominantly hypoactive? 
Palliative sedation: 
• What are the efficacy and harms of different pharmacological interventions? 
o What are appropriate dosing and titration strategies? 
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• What is the comparative reliability of instruments to monitor sedation and agitation in the 
context of palliative sedation that have been developed specifically in palliative care 
populations? 
Protocol-guided treatment: 
• What are the outcomes of expert consensus protocol-guided treatment in the management of 
delirium in the dying phase and palliative sedation? 
Families/carers: 
What are the optimal education and support strategies for families and carers with a loved one 
experiencing refractory delirium or receiving palliative sedation? 
a
 See also “An Analytical Framework for Delirium Research in Palliative Care Settings,”
17
 in this Special 
Section. 
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Figure 1. End-of-Life delirium: framework for clinical decision-making and designation of non-reversible and refractory delirium outcomes  
 
 
 
 
 
 
 
 
 
  
 
 
  
 Discussion to establish / clarify / review Goals of Care and decide on most appropriate delirium management  
 Provide ongoing communication, education, and emotional support for patient, families and healthcare staff 
 Consider palliative care consultation to help with End-of-Life (EoL) decision-making or symptom management 
 Aim to both reverse delirium and treat 
symptoms: use available resources to identify 
the modifiable precipitants of delirium and 
apply precipitant modifying treatments along 
with optimal symptom-directed treatment 
 Aim to solely control symptoms of delirium:          
not to pursue investigation or treatment of 
precipitants but provide optimal symptom-
directed treatment with the aim of ensuring 
comfort 
Laboratory and other Investigations Symptom-directed treatment 
Modifiable 
precipitants 
identified and 
treated 
No modifiable 
precipitants identified 
Pharmacological  Environmental 
modification ‡ 
Minimal sedation approach* 
More sedating approach† 
Non-reversible delirium 
Delirium 
reversed 
Refractory distress due to delirium 
or other symptom at EoL: 
Palliative Sedation 
*Non-sedating typical or atypical antipsychotic;   †Add rescue dose of benzodiazepine or change to sedating antipsychotic to 
specifically achieve mild to moderate levels of sedation as a goal ; ‡Includes other non-pharmacological approaches. 
